Lymphedema

Lymphatic System Function and Dysfunction

• The lymphatic system normally returns interstitial fluid (20L/day) to the venous circulation through a network of lymphatic capillaries, collecting vessels, lymph nodes, and lymphatic trunks
• Lymphatic fluid propulsion occurs through intrinsic vessel contractility (lymphangions), skeletal muscle pump activation, arterial pulsation, and external tissue pressure
• Primary insufficiency results from congenital hypoplasia, aplasia, or hyperplasia of lymphatic vessels (typically presenting in young patients with no antecedent event)
• Secondary insufficiency develops when normal lymphatic capacity is overwhelmed by increased lymph production or reduced drainage capacity

Molecular and Cellular Mechanisms

• Protein accumulation paradox: Because lymphedema fluid contains 1-5g/100mL protein (compared to <2g/100mL in venous edema), osmotic gradient perpetuates fluid retention despite normal capillary hydrostatic pressure
• Loss of lymphatic endothelial cells expressing VEGFR-3 (vascular endothelial growth factor receptor-3) impairs lymphangiogenesis and vessel development
• Inflammatory cascade activation: accumulating lymphatic fluid promotes macrophage infiltration, TH1/TH17 polarization, and fibroblast activation
• Adipose tissue transformation: chronic inflammation and reduced oxygen tension promote fibroadipose tissue deposition, making later stages of lymphedema difficult to reverse
• Impaired immune surveillance: lymphedema predisposes to infection (cellulitis, lymphangitis) due to defective antigen presentation and reduced T-cell trafficking

Hemodynamic and Structural Changes

• Initial stage involves reversible interstitial fluid accumulation without fibrosis
• Progressive fibrosclerotic transformation with collagen deposition, tissue hardening, and skin changes (hyperkeratosis, papillomatosis, lymphangiectasia)
• Increased interstitial fluid pressure leads to microvascular collapse and hypoxia, perpetuating inflammation
• Lymphatic vessel dysfunction: reduced contractility, valve incompetence, and collateral channel development

Primary (Congenital) Lymphedema

• Lymphatic hypoplasia (most common primary type; 4:1 female predominance; bilateral in 10%)
• Lymphatic aplasia (absence of regional lymph nodes/vessels; associated with Milroy disease—FLT4 gene mutation)
• Lymphangiectasia (abnormal lymphatic vessel dilation; may be diffuse or localized)
• Klippel-Trenaunay syndrome (port-wine stain, venous abnormalities, lymphedema; PTEN or PIK3CA mutations)
• Turner syndrome (45,X karyotype; 25% develop lymphedema, especially lower extremities)
• Lymphedema-distichiasis syndrome (FOXC2 mutation; double row of eyelashes, cleft palate, venous abnormalities)

Secondary (Acquired) Lymphedema

• Cancer surgery: axillary/inguinal node dissection (breast, melanoma, gynecologic malignancies); affects 20-30% post-mastectomy, 5-10% post-lumpectomy; risk increases with sentinel lymph node biopsy in certain populations
• Cancer radiation therapy: fibrosis of lymph nodes and vessels; cumulative dose-dependent (threshold ~50 Gy); combined surgery + radiation dramatically increases risk
• Malignancy: direct tumor infiltration of lymph nodes or lymphatic vessels
• Infection: repeated cellulitis/lymphangitis causes scarring and valve destruction; endemic in developing nations (lymphatic filariasis by Wuchereria bancrofti affects 120 million people globally)
• Venous insufficiency: chronic venous hypertension overwhelms lymphatic drainage capacity ("phlebolymphedema")
• Obesity: increased interstitial fluid production and reduced physical activity
• Immobility/paralysis: loss of muscle pump function (post-stroke, spinal cord injury, severe arthritis)
• Cardiovascular surgery: axillary vein dissection, internal mammary artery harvesting, extensive node dissection
• Trauma/burn injuries: damage to lymphatic vessels and formation of scar tissue
• Lipedema: primary disorder of subcutaneous adipose tissue (distinct from lymphedema but may coexist; predominantly affects women, family history common)

Risk Factors for Progression

• Higher BMI and obesity
• Advanced cancer stage and nodal involvement
• Combined modality therapy (surgery + radiation)
• Infection episodes
• Poor compliance with compression therapy
• Upper vs. lower extremity involvement (upper extremity generally worse prognosis)

Cardinal Symptoms

• Progressive, painless swelling of affected extremity (typically unilateral in secondary, bilateral in primary); may be initially pitting, becoming non-pitting with chronicity
• Heavy, full sensation in limb; fatigue from increased limb weight
• Reduced range of motion and functional impairment of joint
• Heaviness and tightness, particularly after prolonged standing or heat exposure
• Acute flare episodes with erythema, warmth, and systemic symptoms (cellulitis; typically caused by beta-hemolytic streptococci or Staphylococcus aureus)

Physical Examination Findings

• Pitting edema that resolves with elevation overnight
• Absence of skin changes or fibrosis
• Normal skin appearance and temperature

• Non-pitting edema resistant to elevation
• Stemmer sign positive (inability to pinch/lift skin fold on dorsum of second toe/finger—pathognomonic for lymphedema)
• Skin thickening and induration; loss of normal skin lines
• Mild hyperkeratosis and papillomatosis
• Temperature elevation compared to contralateral side
• Possible hyperpigmentation
• Circumferential measurements show ≥2cm difference vs. contralateral limb (diagnostic threshold)

• Massive irreversible swelling with severe skin changes
• Hyperkeratosis, papillomatosis, verrucous hyperplasia (resembles orange peel or "cobblestone")
• Potential lymphorrhea (weeping of lymph through skin breaks)
• Skin prone to ulceration, chronic wounds
• Lymphangiectasia (visible dilated lymphatic vessels appearing as nodules)
• Functional disability with significantly impaired mobility
• Psychological distress and body image concerns

Regional Presentation Specifics

• Upper extremity lymphedema (post-breast cancer): hand/finger swelling often first sign; "wedding ring sign" (rings difficult to remove); difficulty with bra fitting; weakness when lifting
• Lower extremity lymphedema: foot/ankle swelling typically initial; difficulty with shoe fitting; restricted walking tolerance; increased fall risk
• Genital/trunk lymphedema: less common but more psychologically distressing; may involve genitals, anterior abdomen, or back

Associated Findings

• Reduced skin turgor and elasticity
• Cool extremity temperature (if venous insufficiency coexists)
• Palpable lymph node enlargement at draining stations (if secondary to ongoing malignancy)
• Cellulitis/lymphangitis: acute onset erythema, lymphatic streaking, systemic fever, chills, malaise

Clinical Diagnosis (Primary Approach)

• Stemmer sign: inability to lift skin fold on dorsum of second digit; sensitivity ~90% for lymphedema, highly specific
• Circumferential measurement: difference ≥2cm compared to contralateral limb at same anatomic landmark (most practical, reproducible method for severity staging)
• Pitting vs. non-pitting assessment: early edema pits with pressure; chronic lymphedema becomes non-pitting
• Timeline: gradual, progressive onset in secondary lymphedema (typically months to years after cancer treatment); spontaneous onset in primary forms

Laboratory Findings

• No specific laboratory tests diagnose lymphedema; labs primarily rule out other causes
• Serum albumin: normal (helps exclude nephrotic syndrome or severe liver disease)
• Thyroid function (TSH, free T4): normal (hypothyroidism causes myxedema, which mimics lymphedema)
• Renal function and proteinuria: evaluate for nephrotic causes of edema
• D-dimer and coagulation studies: only if DVT suspected based on acute unilateral calf swelling with pain/erythema

Imaging Studies

• Technetium-99m or indium-111 labeled antimony sulfide colloid injected intradermally in first web space or medial foot
• Normal pattern: bilateral symmetric clearance from injection site to regional nodes within 1-2 hours
• Lymphedema pattern: delayed tracer clearance (>2-3 hours), asymmetric accumulation at injection site ("pooling"), absent or delayed regional nodal uptake, asymmetric lymphatic vessel visualization
• Primary lymphedema patterns: hypoplastic (absent vessels/nodes), hyperplastic (dilated vessels with functioning nodes), aplastic (no uptake)
• Secondary lymphedema patterns: patchy uptake, collateral vessel development, asymmetric drainage
• Sensitivity/specificity: ~90% for lymphedema diagnosis; distinguishes primary from secondary; quantifies drainage impairment
• Limitation: radiation exposure, time-consuming

• T2-weighted images: hyperintense fluid in subcutaneous tissues; diffuse vs. localized patterns
• Direct MR lymphangiography: gadolinium-enhanced sequences visualize lymphatic vessels and nodes
• Advantages: no radiation, detailed anatomic information, assesses skin/subcutaneous changes, detects fibrosis/adipose infiltration
• Findings: dilated lymphatic vessels, absent lymph nodes, pathologic lymph node enhancement (concerning for malignancy), skin thickening
• Limitation: higher cost, longer acquisition time; less specific for functional assessment

• Primary role: exclude venous obstruction (DVT, superior vena cava syndrome, IVC obstruction)
• Lymphedema findings: diffuse subcutaneous edema without specific venous pathology; may show enlarged lymph nodes
• Advantages: real-time imaging, no radiation, assesses compressibility and flow
• Limitation: operator-dependent; poor visualization of deep lymphatic vessels

• Not first-line for lymphedema diagnosis (non-specific findings)
• Uses: exclude malignancy causing obstruction (mediastinal masses, abdominal tumors, pelvic node enlargement) in secondary cases; evaluate for infection/abscess formation
• Findings: diffuse subcutaneous edema, tissue thickening, possible mass lesions

• Near-infrared fluorescent imaging of lymphatic vessels after intradermal ICG injection
• Advantages: real-time visualization, no radiation, determines lymphatic function and distribution
• Patterns in lymphedema: absent or dilated vessels, abnormal dermal backflow (indicates impaired drainage)
• Limitation: not widely available; primarily research/specialty centers

Diagnostic Criteria (International Society of Lymphology—ISL)

• Stage 0 (At-risk): no edema present; altered lymph transport demonstrable by imaging
• Stage 1 (Spontaneously Reversible): pitting edema, resolves with limb elevation overnight
• Stage 2 (Spontaneously Irreversible): non-pitting edema resistant to elevation; skin/tissue changes (fibrosis, hyperkeratosis); Stemmer sign positive
• Stage 3 (Lymphostatic Elephantiasis): severe irreversible swelling, massive skin changes, functional impairment

General Principles

• Goals: reduce edema volume, prevent progression, improve function, prevent complications (infection), optimize quality of life
• No cure for lymphedema; treatment is lifelong management
• Multimodal approach combining physical therapy, compression, and patient education most effective
• Early intervention within 6 months of cancer surgery prevents progression and is most cost-effective
• Assess adherence, patient motivation, and barriers to compliance

First-Line Comprehensive Decongestive Therapy (CDT)

• Manual lymphatic drainage (MLD): specialized massage technique using light pressure (30-40 mmHg) to stimulate lymphatic vessel contractility and redirect flow toward functioning lymph nodes; 45-60 minute sessions, 5 days/week for 2-4 weeks
• Certified lymphedema therapist essential (specific hand techniques required)
• Most effective when combined with compression
• Compression therapy: graduated compression garments (20-30 mmHg for mild, 30-40 mmHg for moderate, 40-60 mmHg for severe) worn during day; nighttime compression optional
• Materials: elastic, inelastic (short-stretch), or multi-layer systems
• Custom-fitted garments more effective than off-the-shelf
• Replacement every 3-6 months as elasticity degrades
• Skin care regimen: meticulous hygiene, emollient application (unscented lotion, mineral oil), nail care, prevention of breaks/abrasions
• Therapeutic exercise: active range of motion, breathing exercises (diaphragmatic respiration enhances thoracic duct drainage), progressive resistive training
• Contraindication: heavy lifting or strenuous exercise during acute phase; light activity encouraged

• Continued compression garment use: daily wearing essential to prevent reaccumulation
• Self-manual lymphatic drainage: patient-taught simplified techniques (simplified lymphatic drainage—SLD) or self-massage for 10-15 minutes daily
• Regular exercise: low-impact activities (walking, swimming, cycling) 30-60 minutes most days
• Skin care continuation: lifelong attention to hygiene and injury prevention

Adjunctive Pharmacologic Therapy

• Diuretics: generally not recommended as monotherapy (exacerbate protein concentration, worsen edema); acceptable only as brief adjunct for acute inflammation if infection ruled out
• Selenium (oral supplement 200 mcg daily): weak evidence for improved symptoms in some studies; may reduce cellulitis frequency; mechanism unclear
• Flavonoids (diosmin, hesperidin): limited evidence; may improve lymphatic contractility; not FDA-approved in US
• Topical NSAIDs and corticosteroids: limited role; reduce inflammation during acute flares
• Antibiotics: only for cellulitis/lymphangitis (penicillin, amoxicillin-clavulanate, or first-generation cephalosporin); prophylactic antibiotics NOT recommended for routine lymphedema management unless recurrent infections

Interventional Therapies (Selected Cases)

• Microsurgical technique: creates bypass between lymphatic collector vessels and regional veins (typically saphenous or axillary vein)
• Indications: early to moderate lymphedema (Stage 1-2), adequate lymphatic vessel visualized on ICG lymphography or lymphoscintigraphy, failed CDT compliance/response
• Success rates: 40-70% volume reduction in appropriately selected candidates; prevents progression; may reduce compression therapy needs
• Timing: ideally performed within 1-2 years of lymphedema onset before extensive fibrosis develops
• Limitations: requires specialized microsurgical expertise; high cost; not widely available; benefits plateau after 2 years

Infectious (the dominant complication)

• Recurrent cellulitis/erysipelas: stagnant protein-rich lymph is an ideal culture medium, and impaired dendritic-cell/T-cell trafficking cripples local immune surveillance; each episode destroys more lymphatics, creating a self-amplifying cycle. Signal: abrupt fever, chills, and a sharply demarcated erythematous plaque on the swollen limb. Per the IDSA skin and soft tissue infection guideline, non-purulent cellulitis is treated as streptococcal (beta-lactam such as penicillin or cefazolin); IDSA endorses suppressive prophylaxis (e.g., penicillin) only for patients with several episodes per year despite optimized decongestive care.
• Sepsis and necrotizing fasciitis — emergencies. Pain out of proportion to exam, rapidly advancing margins, bullae, crepitus, or hypotension mandate immediate broad-spectrum antibiotics and surgical exploration; imaging must not delay debridement.
• Lymphangitis: tender red streaks tracking proximally with regional adenopathy.

Cutaneous and structural

• Lymphorrhea and ulceration: interstitial pressure exceeds dermal integrity, producing weeping portals of entry that seed infection.
• Fibroadipose deposition and elephantiasis: irreversible once collagen and fat replace fluid — the reason ISL staging drives the urgency of early therapy.
• Stewart-Treves syndrome: cutaneous angiosarcoma in a chronically lymphedematous limb, classically years after axillary dissection for breast cancer. Signal: violaceous macules, nodules, or ecchymosis-like plaques that do not resolve. Requires urgent biopsy — this is a lethal, often-missed malignancy.
• Functional decline, falls, and depression from limb weight and disfigurement; NCCN survivorship guidance emphasizes screening for psychosocial distress.

Treatment-related

• Compression in undiagnosed peripheral arterial disease: external pressure superimposed on low perfusion causes ischemic necrosis — check ankle-brachial index before high-grade compression in lower-limb disease.
• Compression/pneumatic pumps in decompensated heart failure: rapid central fluid translocation can precipitate pulmonary edema; pumps may also displace fluid into the genitalia or trunk.
• Diuretics: remove water but not protein, concentrating interstitial oncotic load and risking volume depletion — a common iatrogenic error.
• Manual lymphatic drainage is deferred during acute cellulitis, untreated DVT, or active nodal malignancy.
• Microsurgery (LVA, node transfer, liposuction): anastomotic thrombosis, wound infection, and donor-site lymphedema.

• Positive Stemmer sign (cannot tent the skin over the dorsum of the second toe/finger) is the single most tested bedside finding — it distinguishes lymphedema from venous or cardiac edema, in which the skin pinches easily.
• Lymphedema involves the foot and toes; venous insufficiency spares them. Venous disease gives hemosiderin staining, medial malleolar (gaiter-zone) ulcers, and varicosities; lymphedema gives squared toes, peau d'orange, and a positive wedding-ring sign in the arm. Lipedema is bilateral, tender, symmetric fat that stops abruptly at the ankle (cuff sign) with a negative Stemmer sign.
• The one association examiners love: chronic post-mastectomy arm lymphedema plus new violaceous nodules = Stewart-Treves cutaneous angiosarcoma. Best next step is biopsy, not antibiotics — the classic distractor is calling it cellulitis.
• Genetics grid: Milroy disease = congenital, FLT4/VEGFR-3 mutation; Meige disease (lymphedema praecox) = onset at puberty, the most common primary form; lymphedema-distichiasis = FOXC2 with a double row of eyelashes. Nonpitting puffy hands and feet in a newborn girl with webbed neck = Turner syndrome.
• Worldwide the leading cause is filariasis (Wuchereria bancrofti): diagnosis by nocturnal peripheral blood smear for microfilariae (or circulating filarial antigen); WHO mass drug administration uses diethylcarbamazine-based or ivermectin-albendazole regimens — screen for onchocerciasis/loiasis co-infection before DEC or ivermectin.
• Best initial and mainstay therapy is complete decongestive therapy — manual lymphatic drainage plus graduated compression, skin care, and exercise. If a stem offers furosemide, it is wrong: diuretics do not clear interstitial protein and cause volume depletion.
• Check arterial perfusion before compressing a leg. Compression over unrecognized peripheral arterial disease can cause ischemic necrosis.
• Acutely red, hot, painful swollen limb: treat as streptococcal cellulitis with a beta-lactam per IDSA; escalate immediately for pain out of proportion, bullae, or crepitus (necrotizing infection). Also keep DVT on the differential for sudden unilateral swelling — get duplex ultrasound.